DNB Markets investment case and
how we differ from consensus:
-
We assume strong sales growth and
believe Photocure could achieve
attractive margins. -
We have not factored in additional
M&A, even though we connsder it
highly likely from 2024. -
We have not included any value from
the Cevira project, out-licensed to
Asieris since 2019 (except some highprobability short-term milestones).